Novartis' Fabhalta Approved by FDA for C3 Glomerulopathy Treatment
CompanyDrug

Novartis’ Fabhalta Approved by FDA for C3 Glomerulopathy Treatment

Sino Biopharmaceutical's 2024 Revenue Up 10.2% on Strong Innovative Drug Sales
Company

Sino Biopharmaceutical’s 2024 Revenue Up 10.2% on Strong Innovative Drug Sales

Arcutis Biotherapeutics' Zoryve Cream Nears FDA Approval for Pediatric Atopic Dermatitis
CompanyDrug

Arcutis Biotherapeutics’ Zoryve Cream Nears FDA Approval for Pediatric Atopic Dermatitis

Sanofi to Acquire DR-0201 for $600 Million to Advance Myeloid Cell Engager
CompanyDeals

Sanofi to Acquire DR-0201 for $600 Million to Advance Myeloid Cell Engager

Kexing Biopharm and Hinova Forge Alliance to Expand Global Market Reach
CompanyDeals

Kexing Biopharm and Hinova Forge Alliance to Expand Global Market Reach

Kintor Pharmaceutical's KX-826 Shows Promising Results in Alopecia Phase III Trial
CompanyDrug

Kintor Pharmaceutical’s KX-826 Shows Promising Results in Alopecia Phase III Trial

Junshi Biosciences Receives NMPA Approval for JS212 in Advanced Solid Tumors
CompanyDrug

Junshi Biosciences Receives NMPA Approval for JS212 in Advanced Solid Tumors

Hengrui's Trastuzumab Rezetecan Nears 8th Breakthrough Therapy Designation
CompanyDrug

Hengrui’s Trastuzumab Rezetecan Nears 8th Breakthrough Therapy Designation

Fosun's Henlius Receives FDA Orphan Drug Designation for HER2-Targeting HLX22
CompanyDrug

Fosun’s Henlius Receives FDA Orphan Drug Designation for HER2-Targeting HLX22

Paratek Pharmaceuticals to Acquire Optinose for $330 Million
CompanyDeals

Paratek Pharmaceuticals to Acquire Optinose for $330 Million

Boji Medicine's Huasheng Transfers Glucosamine Sulfate Capsules Technology to Panlong
CompanyDeals

Boji Medical’s Huasheng Transfers Glucosamine Sulfate Capsules Technology to Panlong

Oxford BioTherapeutics Partners with Roche on Cancer Therapeutics Discovery
CompanyDeals

Oxford BioTherapeutics Partners with Roche on Cancer Therapeutics Discovery